Related Experiment Video
Updated: Sep 20, 2025
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Pluripotent stem cell-derived cardiomyocyte transplantation: marching from bench to bedside
Yi Hong1,2, Jiarui Liu1, Weixuan Wang1
1Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Center for Non-coding RNA Medicine, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Insights
Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) offer a promising solution for cardiac regeneration, addressing limitations in treating heart diseases. This review covers advancements, challenges like immune rejection, and clinical progress in PSC-CM transplantation (PCT).
Area of Science:
- Regenerative Medicine
- Cardiology
- Stem Cell Biology
Background:
- Cardiovascular diseases remain a leading cause of mortality worldwide.
- Limited regenerative capacity of adult human hearts restricts current treatment efficacy.
- Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) present a potential therapeutic strategy for cardiac repair.
Purpose of the Study:
- To review the latest advancements and future prospects of PSC-CM transplantation (PCT).
- To discuss existing challenges in PCT, including immune rejection and engraftment arrhythmias.
- To explore potential solutions and the progression of PCT from preclinical research to clinical trials.
Main Methods:
- Comprehensive literature review of fundamental research, preclinical studies, and clinical trials.
- Analysis of current data on PSC-CM generation and characterization.
- Evaluation of strategies to overcome transplantation barriers.
Main Results:
- PSC-CM transplantation shows promise for cardiac regeneration.
- Immune rejection and arrhythmias are significant hurdles in PCT.
- Ongoing research and clinical trials are actively addressing these constraints.
Conclusions:
- PCT is a rapidly advancing field with significant therapeutic potential for cardiovascular diseases.
- Overcoming immunological barriers and ensuring safe engraftment are critical for clinical success.
- Translational efforts are moving PCT from bench to bedside, offering hope for improved cardiac repair.
Abstract:
Cardiovascular diseases such as myocardial infarction, heart failure, and cardiomyopathy, persist as a leading global cause of death. Current treatment options have inherent limitations, particularly in terms of cardiac regeneration due to the limited regenerative capacity of adult human hearts. The transplantation of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) has emerged as a promising and potential solution to address this challenge. This review aims to summarize the latest advancements and prospects of PSC-CM transplantation (PCT), along with the existing constraints, such as immune rejection and engraftment arrhythmias, and corresponding solutions. Encompassing a comprehensive range from fundamental research findings and preclinical experiments to ongoing clinical trials, we hope to offer insights into PCT from bench to bedside.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
08:03Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022